Is it Time to Cash Out Novavax Stock?

Published on July 19, 2022

Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S.

Continue reading on website
Other news

Japanese e-commerce enabler AnyMind raises funding in equity, debt for acquisitions

July 19, 2022
The pandemic has triggered more demand for online shopping and fueled many smaller retailers to establish their own online offerings. Japanese commerce enabler AnyMind, which helps brands and influencers’ online operations, has closed a ¥5 billion (approximately $36 million) Series D round on the back of that boost to make additional acquisitions in Japan and globally.The Series D funding, which b

When You Silence the Noise, AMD Stock Still Offers Strong Fundamentals

July 19, 2022
Advanced Micro Devices (NASDAQ:AMD) is illustrative of how quickly sentiment can turn. From the onset of the Covid-19 pandemic to the end of November 2021, AMD stock climbed 290%.